HQK 1001 / Viracta Therap  >>  Phase 2
Welcome,         Profile    Billing    Logout  

6 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
HQK 1001 / Viracta Therap
NCT01322269: A Study of HQK-1001 in Patients With Sickle Cell Disease

Completed
2
52
US, Canada, RoW
HQK-1001
HemaQuest Pharmaceuticals Inc.
Sickle Cell Disease, Sickle Cell Anemia, Sickle Cell Disorders, Hemoglobin S Disease, Sickling Disorder Due to Hemoglobin S
03/12
 
NCT01609595: Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand

Completed
2
10
RoW
sodium 2,2 dimethylbutyrate, HQK-1001, ST20
Boston University, Mahidol University
Beta Thalassemia Intermedia
11/12
12/12
LB-04-THAL, NCT01642758: Trial of HQK-1001 in Beta Thalassemia Intermedia in Lebanon

Completed
2
10
RoW
Sodium 2,2 dimethylbutyrate, ST20
Boston University, HemaQuest Pharmaceuticals Inc.
Beta Thalassemia Intermedia
11/12
01/13
NCT01601340: Effects of HQK-1001 in Patients With Sickle Cell Disease

Terminated
2
77
US, Canada, RoW
HQK-1001, Placebo
HemaQuest Pharmaceuticals Inc.
Sickle Cell Disease, Sickle Cell Anemia, Sickle Cell Disorders, Hemoglobin S Disease, Sickling Disorder Due to Hemoglobin S
11/13
12/13
NCT00790127: Phase 1/2 Study of HQK-1001 in Patients With Beta Thalassemia

Completed
1/2
21
RoW
HQK-1001, Placebo
HemaQuest Pharmaceuticals Inc.
Beta Thalassemia
05/10
05/10
NCT00842088: Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HQK-1001 Administered Daily in Patients With Sickle Cell Disease

Completed
1/2
24
US, RoW
Placebo, HQK-1001
HemaQuest Pharmaceuticals Inc.
Sickle Cell Disease
07/10
 

Download Options